Literature DB >> 4071392

Further evidence of the validity of risk group definition in differentiated thyroid carcinoma.

B Cady, R Rossi, M Silverman, M Wool.   

Abstract

Three hundred nine consecutive patients primarily treated at the Lahey Clinic Foundation for differentiated thyroid carcinoma between the years 1961 and 1980 were followed for a median of 13 years and a minimum of 5 years. The recurrence and survival rates of these patients are strikingly different in the low-risk group (men 40 years of age and under and women 50 years and under) compared with the high-risk group (all older patients). Only two patients died and eight others had recurrences but survived in 192 low-risk patients, whereas 18 died and 23 had recurrences in 117 high-risk patients. Thus 20% of patients with recurrence in the low-risk group died but 78% of patients with recurrence in the high-risk group died. Follicular carcinoma and major capsular invasion carries a poor prognosis, but only 22% of low-risk in contrast to 55% of high-risk patients died. The fact that low- and high-risk patients have a separate biology is emphasized by unique sex ratio differences. Low-risk patients have a constant male to female ratio of about 5:1, whereas high-risk patients have progressively increased from 1:3 to a male predominance during the past 5 decades. This study showing unique differences in results by age reemphasizes the concept of basic risk groups in differentiated thyroid cancer. The effect of this basic risk group, as in our previous report, supercedes the effect of pathologic type, extent of local disease, or aspects of therapy and exerts principal control over biologic behavior.

Entities:  

Mesh:

Year:  1985        PMID: 4071392

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  26 in total

1.  Encapsulated papillary thyroid carcinoma: is it a distinctive clinical entity with low-grade malignancy?

Authors:  A Pisanu; D Deplano; I Reccia; G Porceddu; A Uccheddu
Journal:  J Endocrinol Invest       Date:  2012-01-31       Impact factor: 4.256

2.  Papillary microcarcinoma: is there any difference between clinically overt and occult tumors?

Authors:  Chung-Yau Lo; Wai-Fan Chan; Brian Hung-Hin Lang; King-Yin Lam; Koon-Yat Wan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group.

Authors:  K D Newman; T Black; G Heller; R G Azizkhan; G W Holcomb; C Sklar; V Vlamis; G M Haase; M P La Quaglia
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

4.  Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness.

Authors:  A E Siperstein; Q H Zeng; E T Gum; K E Levin; O H Clark
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

5.  Current results of conservative surgery for differentiated thyroid carcinoma.

Authors:  R L Rossi; B Cady; M L Silverman; M S Wool; T A Horner
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

6.  An analysis of lymphocyte subsets in the regional lymph nodes of patients with papillary thyroid carcinoma.

Authors:  K Sugino
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Hop S Tran Cao; Lily E Johnston; David C Chang; Michael Bouvet
Journal:  Surgery       Date:  2012-04-11       Impact factor: 3.982

8.  Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131)

Authors:  M Coburn; D Teates; H J Wanebo
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

9.  Follicular thyroid carcinoma invades venous rather than lymphatic vessels.

Authors:  Xiaoqi Lin; Bing Zhu; Yulin Liu; Jan F Silverman
Journal:  Diagn Pathol       Date:  2010-01-22       Impact factor: 2.644

10.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.